0.10 (0.87%)

Scroll for more



Analyst Coverage

Sucampo is followed by the analysts below




Guggenheim Securities, LLC

Louise Chen

H.C. Wainwright & Co., LLC

Ed Arce


David Steinberg

Leerink Partners LLC

Jason Gerberry

Maxim Group, LLC

Jason Kolbert

Mizuho Securities USA, Inc

Irina R. Koffler

Northland Securities

David Buck

Roth Capital Partners, LLC

Michael Higgins

UBS Securities LLC

Ami Fadia

WallachBeth Capital LLC

Brian Jeep

Please note that any opinions, estimates or forecasts regarding Sucampo’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sucampo or its management. Sucampo does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.



Silvia Taylor

Senior Vice President, Investor Relations and Corporate Affairs


Phone: +1-240-223-3718

Contact Us
Tel: +1-301-961-3400

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.